Peripartum Cardiomyopathy

Cardiology Clinics

Volumn 30, Issue 3, 2012, Pages 435-440

  Elkayam, Uri ^a   Jalnapurkar, Sawan ^a   Barakat, Mohamad ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

BNP; Bromocriptine; Cardiac transplantation; Heart failure; Pentoxifylline; Peripartum cardiomyopathy; Pregnancy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BRAIN NATRIURETIC PEPTIDE; BROMOCRIPTINE; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; FUROSEMIDE; GLYCERYL TRINITRATE; HEPARIN DERIVATIVE; INOTROPIC AGENT; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; MILRINONE; NESIRITIDE; NITROPRUSSIDE SODIUM; PENTOXIFYLLINE; SPIRONOLACTONE; VASODILATOR AGENT; WARFARIN;

AFRICAN AMERICAN; CARDIOGENIC SHOCK; CARDIOVASCULAR RISK; CLINICAL FEATURE; DEFIBRILLATOR; DELIVERY; DISEASE CONTROL; DISEASE SEVERITY; EMBRYOTOXICITY; EXPERIMENTAL STUDY; FETUS MATURITY; HEART ARRHYTHMIA; HEART ASSIST DEVICE; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART TRANSPLANTATION; HUMAN; HYPERTENSION; INCIDENCE; LABOR; LABORATORY TEST; LACTATION; LUNG EDEMA; MATERNAL MORTALITY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PATIENT MONITORING; PERIPARTUM CARDIOMYOPATHY; PRACTICE GUIDELINE; PREECLAMPSIA; PREGNANCY TERMINATION; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REVIEW; SYMPTOM; THROMBOEMBOLISM; UNITED STATES;

BIOLOGICAL MARKERS; CARDIOMYOPATHIES; DEFIBRILLATORS, IMPLANTABLE; DELIVERY, OBSTETRIC; FEMALE; HEART FAILURE; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PREGNANCY OUTCOME; PROGNOSIS; RECOVERY OF FUNCTION; RISK FACTORS; THERAPIES, INVESTIGATIONAL;

EID: 84863866260     PISSN: 07338651     EISSN: 15582264     Source Type: Journal    
DOI: 10.1016/j.ccl.2012.04.009     Document Type: Review

References (43)

1. Demakis J.G., Rahimtoola S.H., Sutton G.C., et al. Natural course of peripartum cardiomyopathy. Circulation 1971, 44:1053-1061.
2. Pearson G.D., Veille J.C., Rahimtoola S.H., et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA 2000, 283:1183-1188.
3. Hibbard J.U., Lindheimer M., Lang R. A modified definition for peripartum cardiomyopathy and prognosis based on echocardiography. Obstet Gynecol 1999, 94:311-316.
4. Lang R.M., Lampert M.B., Poppas A., et al. Peripartal cardiomyopathy. Cardiac problems in pregnancy 1998, 87-100. Wiley-Liss Inc, New York. 3rd edition. U. Elkayam, N. Gleicher (Eds.).
5. Elkayam U., Akhter M.W., Singh H., et al. Pregnancy-associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation. Circulation 2005, 11:2050-2055.
6. Anderson J.L., Horne B.D. Birthing the genetics of peripartum cardiomyopathy. Circulation 2010, 121:2157-2159.
7. Sliwa K., Hilfiker -Kleiner D., Petrie M.C., et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 2010, 12:767-778.
8. Witlin A.G., Mabie W.C., Sibai B.M. Peripartum cardiomyopathy: an ominous diagnosis. Am J Obstet Gynecol 1997, 176:182-188.
9. Chapa J.B., Heiberger H.B., Weinert L., et al. Prognostic value of echocardiography in peripartum cardiomyopathy. Obstet Gynecol 2005, 105:1303-1308.
10. Mielniczuk L.M., Williams L., Davis D.R., et al. Frequency of peripartum cardiomyopathy. Am J Cardiol 2006, 97:1765-1768.
11. Brar S.S., Khan S.S., Sandha G.K., et al. Incidence, mortality, and racial differences in peripartum cardiomyopathy. Am J Cardiol 2007, 100:302-304.
12. Desai D., Moodley J., Naidoo D. Peripartum cardiomyopathy: experience at King Edward VIII Hospital, Durban, South Africa and review of the literature. Trop Doct 1995, 25:118-123.
13. Fett J.D., Christie L.G., Caraway R.D., et al. Five year prospective study of the incidence and properties of peripartum cardiomyopathy at a single institution. Mayo Clin Proc 2005, 80:1602-1606.
14. Ntusi N.B., Mayosi B.M. Aetiology and risk factors of peripartum cardiomyopathy a systematic review. Int J Cardiol 2009, 131:168-179.
15. Hilfiker-Kleiner D., Kaminski K., Podewski E., et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 2007, 128:589-600.
16. Morales A., Painter T., Li R., et al. Rare variant mutations in pregnancy-associated or peripartum cardiomyopathy. Circulation 2010, 121:2176-2182.
17. Van Spaendonck-Zwarts K.Y., van Tintelen J.P., van Veldhuisen D.J., et al. Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. Circulation 2010, 121:2169-2175.
18. Goland S., Modi K., Bitar F., et al. Clinical profile and predictors of complications in peripartum cardiomyopathy. J Card Fail 2009, 15:645-650.
19. Resnik J.L., Hong C., Resnik R., et al. Evaluation of B-type natriuretic peptide (BNP) levels in normal and preeclamptic women. Am J Obstet Gynecol 2005, 193:450-454.
20. Forster O., Hilfiker-Kleiner D., Ansari A.A., et al. Reversal of IFN-gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy. Eur J Heart Fail 2008, 10:861-868.
21. Hu C.L., Li Y.B., Fang J.H., et al. Troponin T measurement can predict persistent left ventricular dysfunction in peripartum cardiomyopathy. Heart 2007, 93:488-490.
22. Whitehead S.J., Berg C.J., Chang J. Pregnancy-related mortality due to cardiomyopathy; United States, 1991-1997. Obstet Gynecol 2003, 102:1326-1331.
23. Lang C.T., King J.C. Maternal mortality in the United States. Best Pract Res Clin Obstet Gynaecol 2008, 22:517-531.
24. Sliwa K., Forster O., Tibarazwa K., et al. Long term outcome of peripartum cardiomyopathy in a population with high seropositivity for human immunodeficiency virus. Int J Cardiol 2011, 147:202-208.
25. Sliwa K., Blauwet Tibazarwa K., et al. Evaluation of bromocriptine in the pilot study. Circulation 2010, 121:1465-1473.
26. Fett J., Carraway R.D., Dowell D.L., et al. Peripartum cardiomyopathy in the Hospital Albert Schweitzer District of Haiti. Am J Obstet Gynecol 2009, 201:171e1-171e5.
27. Duran N., Gunes H., Duran I., et al. Predictors of prognosis in patients with peripartum cardiomyopathy. Int J Obstet Gynecol 2008, 111:2050-2055.
28. Amos A., Jaber W.A., Russel S.D. Improved outcomes in peripartum cardiomyopathy with contemporary. Am Heart J 2006, 152:509-513.
29. Felker G.M., Thompson R.E., Hare J., et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000, 342:1077-1084.
30. Modi K.A., Illum S., Jariatul K., et al. Poor outcome of indigent patients with peripartum cardiomyopathy in the United States. Am J Obstet Gynecol 2009, 201:171-172.
31. Safirstein J.G., Ro A.S., Grandhi S., et al. Predictors of left ventricular recovery in a cohort of peripartum cardiomyopathy patients recruited via the Internet. Int J Cardiol 2012, 154:27-31.
32. Elkayam U., Tummala P.P., Rao K., et al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy. N Engl J Med 2001, 334:1567-1571.
33. Fett J.D., Fristoe K.L., Welsh S.N. Risk of heart failure relapse in subsequent pregnancy among peripartum cardiomyopathy mothers. Int J Gynaecol Obstet 2010, 109:34-36.
34. Lindenfeld J., Albert N.M., Boehmer J.A., et al. Executive summary; HFSA 21006 comprehensive heart failure practice guidelines. J Card Fail 2006, 12:10-38.
35. Bozkurt B., Villaneuva F.S., Holubkov R., et al. Intravenous immune globulin in the therapy of peripartum cardiomyopathy. J Am Coll Cardiol 1999, 34:177-180.
36. Sliwa K., Skudicky D., Candy G., et al. The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy. Eur J Heart Fail 2002, 4:305-309.
37. Reck S., Geller J.C., Meltendorf U., et al. Clinical efficacy of wearable defibrillator in acutely terminating episodes of ventricular fibrillation using biphasic shocks. Pacing Clin Electrophysiol 2003, 26:2016-2022.
38. Bardy G.H., Smith W.M., Hood M.A., et al. An entirely subcutaneous implantable cardioverter - defibrillator. N Engl J Med 2010, 363:36-44.
39. Yang H.S., Hong Y.S., Rim S.J., et al. Extracorporeal membrane oxygenation in a patient with peripartum cardiomyopathy. Ann Thorac Surg 2007, 84:262-264.
40. Oosterom L., de Jonge N., Kirkels J.H., et al. Left ventricular assist device as a bridge for recovery in a young woman admitted with peripartum cardiomyopathy. Neth Heart J 2008, 16:426-428.
41. Zimmerman H., Bose R., Smith R., et al. Treatment of peripartum cardiomyopathy with mechanical assist devices and cardiac transplantation. Ann Thorac Surg 2010, 89:1211-1217.
42. Zimmerman H., Coelho- Anderson R., Smith R., et al. Bridge to recovery with a thoracic biventricular assist device for postpartum cardiomyopathy. ASAIO J 2010, 50:479-480.
43. Rasmusson K., Braunisholz K., Budge D., et al. Peripartum cardiomyopathy: post transplant outcome from the United Network for Organ Sharing database. J Heart Lung Transplant 2012, 31:180-186.